NCT03500302View on ClinicalTrials.gov

Effect of Evolocumab on Coronary Endothelial Function

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 4, 2018

Primary Completion Date

November 30, 2019

Study Completion Date

November 30, 2019

Conditions
Human Immunodeficiency VirusCoronary Artery Disease
Interventions
DRUG

Evolocumab

Evolocumab sq once a month for a total of two doses

Trial Locations (1)

21205

Johns Hopkins University, Baltimore

All Listed Sponsors
collaborator

American Heart Association

OTHER

lead

Johns Hopkins University

OTHER

NCT03500302 - Effect of Evolocumab on Coronary Endothelial Function | Biotech Hunter | Biotech Hunter